Oncolytics Biotech Announces Listing on Nasdaq Capital Market

Biotech Investing

Oncolytics Biotech (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that its shares of common stock were approved for listing on the Nasdaq Capital Market. Oncolytics Biotech’s common stock will commence trading on the Nasdaq Capital Market today, June 1, 2018, under the symbol “ONCY”. As quoted in …

Oncolytics Biotech (TSX:ONC) (NASDAQ:ONCY), currently developing REOLYSIN^® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that its shares of common stock were approved for listing on the Nasdaq Capital Market. Oncolytics Biotech’s common stock will commence trading on the Nasdaq Capital Market today, June 1, 2018, under the symbol “ONCY”.

As quoted in the press release:

“Listing on Nasdaq, a premier U.S. stock exchange, represents another significant milestone for Oncolytics and our shareholders,” said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. “As a Nasdaq-listed company, we expect to have the opportunity to broaden our exposure to biotech focused institutional investors, diversify our shareholder base, expand our access to capital, and increase the liquidity of our shares.”
Oncolytics’ common stock will continue to trade on the Toronto Stock Exchange (TSX) under the trading symbol “ONC”.

Click here to read the full press release.

Biotech Investing